Skip to main content

Advertisement

Table 3 Main toxicity in 258 patients according to cTcAE version 4.03

From: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Grade 3–4 toxicities; n (%)
Anemia 4 (1.6)
Neutropenia 54 (20.9)
Thrombocytopenia 1 (0.4)
Liver dysfunction 2 (0.8)
Peripheral neuropathy 10 (3.9)
Febrile neutropenia 13 (5.0)